[Show abstract][Hide abstract] ABSTRACT: This study investigated the expression of nuclear factor κB (NF-κB) and the chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.
The Korean Journal of Internal Medicine 11/2014; 29(6):785-92.
[Show abstract][Hide abstract] ABSTRACT: Previous epidemiologic studies have shown the clinical association between non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). However, there is only limited information about the effect of NAFLD on the development of hypertension. Accordingly, we investigated the clinical association between NAFLD and prehypertension. A prospective cohort study was conducted on the 11,350 Korean men without prehypertension for 5 yr. The incidences of prehypertension were evaluated, and Cox proportional hazard model was used to measure the hazard ratios (HRs) for the development of prehypertension according to the degree of NAFLD (normal, mild, moderate to severe). The incidence of prehypertension increased according to NAFLD states (normal: 55.5%, mild: 63.7%, moderate to severe: 70.3%, P<0.001). Even after adjusting for multiple covariates, the HRs (95% confidence interval) for prehypertension were higher in the mild group (1.18; 1.07-1.31) and moderate to severe group (1.62; 1.21-2.17), compared to normal group, respectively (P for trend <0.001). The development of prehypertension is more potentially associated with the more progressive NAFLD than normal and milder state. These findings suggest the clinical significance of NAFLD as one of risk factors for prehypertension.
Journal of Korean medical science. 07/2014; 29(7):973-9.
[Show abstract][Hide abstract] ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is getting an increasing attention for its clinical implications on cardiovascular disease (CVD). However, epidemiologic data are not so evident to sustain the causative association between NAFLD and hypertension, the major cause of CVD. Accordingly, we designed this study to investigate the clinical association between NAFLD and the development of hypertension.
Journal of Gastroenterology and Hepatology 06/2014; · 3.33 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Eremias argus, which specifically inhabits riverside or coastal sand dune, is an endangered species designated by the Ministry of Environment of Korea because it has been drastically decreasing due to the destruction of habitat and the human activities. Therefore, it is required to prepare a countermeasure for the strategic and systematic solutions for the conservation of the E. argus. This study analyzed mtDNA cytochrome oxidase subunit I (COI) gene of E. argus inhabiting Yoobu-do island and Sohwang sand dune. This study aims to provide fundamental genetic information through phylogeographical analysis between two regions. Of 11 individuals of E. argus used in the analysis, the total 652~656 bp of mtDNA COI genes for 3 individuals of Takydromus wolteri as 'out group' were analyzed. Intraspecific genetic distance for E. argus was shown to be the same result of 0.000. As for T. wolteri, it was 0.005, showing very similar result. T. wolteri inhabiting Gapcheon stream in Daejeon metropolitan city was found to be the highest intraspecific genetic distance (0.008). The NJ tree of E. argus and T. wolteri indicated there was almost no genetic difference between habitat for E. argus. For T. wolteri, however, there was slight difference between the individuals inhabiting Yoobu-do island and those inhabiting Gapcheon stream in Daejeon metropolitan city. Therefore, it is necessary to prepare conservation strategies to increase genetic diversity of E. argus in Yoobu-do island in the future because it is highly presumed that the population of E. argus in Yoobu-do island have been flown from nearby coastal sand dune.
Journal of Asia-Pacific Biodiversity. 12/2013; 6(4).
[Show abstract][Hide abstract] ABSTRACT: The present report describes two chronic myelogenous leukemia (CML) patients with the JAK2-V617F mutation who were in complete hematologic and cytogenetic remission and subsequently developed clinical features of essential thrombocythemia under treatment with tyrosine kinase inhibitors. In light of the findings from previous reports, screening for the JAK2-V617F mutation should be considered for any Ph(+) CML patients with thrombocytosis, leukocytosis, or erythrocytosis at diagnosis and for patients who subsequently develop thrombocytosis, leukocytosis, or erythrocytosis during follow-up, even for CML patients in complete cytogenetic response and major molecular response.
International journal of hematology 04/2013; · 1.17 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: OBJECTIVES: There were many studies for the clinical association between non alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS). However, while most of studies have focused on the unilateral effects of MetS on NAFLD, studies for reverse association were comparatively rare. Therefore, we carried out a prospective cohort study to evaluate the longitudinal effects of NAFLD on the development of MetS according to the degree of NAFLD. PATIENTS AND METHODS: A total of 46,874 men, who had participated in a medical health check-up program in 2005, were enrolled in this study. Out of them, a Mets-free cohort of 11,926 without excluding conditions was followed up until 2010. All participants were classified into 3 groups by their NAFLD status (normal, mild, moderate to severe). The baseline values of metabolic components and the development rates of MetS were compared according to the degree of NAFLD. Cox proportional hazards model was used to measure the hazard ratios (HRs) for MetS according to the degree of NAFLD. RESULTS: During 41,912.1 person-years of follow-up, 1861 incident cases of MetS developed between 2006 and 2010. Even after adjusting for multiple covariates, the HRs (95% CI) for MetS were higher in the mild group (1.49; 1.30-1.70) and moderate to severe group (2.00; 1.46-2.73) compared to normal group, respectively (P for trend <0.001). These associations were apparent in the clinically relevant subgroup analyses. CONCLUSIONS: NAFLD was independent risk factor for MetS during the 5-yr follow-up period.
[Show abstract][Hide abstract] ABSTRACT: There have been several reports about clinical association between type 2 diabetes mellitus (DM) and non-alcoholic fatty liver disease (NAFLD). However, most of studies were about the unilateral effects of type 2 DM on NAFLD, and studies for the reverse relation were rare. Thus, this study was designed to investigate the effect of NAFLD on the type 2 DM. We conducted a prospective cohort study on the 25,232 Korean men without type 2 DM for 5 years. We serially checked the various metabolic factors including fasting glucose and hemoglobin A1c (HbA1c), and monitored the development of type 2 DM. Incidence rate of type 2 DM was compared according to the degree of NAFLD (normal, mild, and moderate to severe), and Cox proportional hazards model was used to measure the hazard ratios (HRs) of NAFLD on type 2 DM. The incidence rate of type 2 DM increased according to the degree of NAFLD (normal: 7.0%, mild: 9.8%, moderate to severe: 17.8 %, P < 0.001). Even after adjusting for other multiple covariates, the HRs (95% CI) for type 2 DM development was higher in mild group (1.09; 0.81-1.48) and moderate to severe group (1.73; 1.00-3.01) compared to normal group, respectively (P for trend <0.001). In conclusion, the development of type 2 DM is more potentially associated with more progressive NAFLD than normal or milder state. In addition, NAFLD was an independent risk factor of future development of type 2 DM. These results suggest the potential availability of NAFLD as an early predictor of type 2 DM. (HEPATOLOGY 2012.).
[Show abstract][Hide abstract] ABSTRACT: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2).
Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively.
The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034).
Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning.
The Korean Journal of Internal Medicine 03/2012; 27(1):72-83.
[Show abstract][Hide abstract] ABSTRACT: Chronic widespread pain (CWP) is known as a common symptom of several organic and psychological disorders. Although medically unexplained CWP (MUE) has lots of clinical distress symptoms, there were no distinct symptoms or signs. Therefore, we conducted this study to investigate clinical distress symptoms of MUE distinct from those of medically explained CWP (ME).
One hundred nine patients with CWP were enrolled in the study. We classified the study subjects into three groups depending on their medical problems associated with CWP: organic group (ORG), psychological group (PSY), and MUE. All subjects were asked to fill out self-report questionnaires consisting of clinical distress scales including the Korean version of the Fibromyalgia Impact Questionnaire (FIQ-K), fatigue scale, depression scale, and stress scale. And physicians examined 18 tender points over their entire body of the subjects.
MUE patients had higher FIQ-K and fatigue severity scores than ORG patients (all P < 0.05). The average number of tender points were 11.33 in MUE patients, 6.48 in ORG patients and 5.02 in PSY patients and statistically significant (P < 0.0001). There were no statistically different factors between MUE and PSY patients with exception for the number of tender points. Depressive symptom was the highest in PSY patients but not statistically different from MUE patients.
MUE patients had higher physical impairments, fatigue severity and more number of tender points than ORG patients, but had no different clinical characteristics from PSY patients except for the number of tender points.
Korean journal of family medicine. 07/2011; 32(5):277-84.
[Show abstract][Hide abstract] ABSTRACT: Cyclin-dependent kinases (CDKs) are involved in the regulation of the cell cycle and the growth of tumor cells. In this study, we investigated the antitumor effect and differentially expressed genes (DEGs) in head and neck cancer cells treated by a novel CDK inhibitor, 2-[1,1'-biphenyl]- 4-yl-N-[5-(1,1-dioxo-1lambda(6)-isothiazolidin-2-yl)-1H-indazol-3-yl] acetamide (BAI).
Cell growth was measured by XTT assay. Cell cycle and apoptosis were determined using flow cytometry. GeneFishing PCR was utilized to identify DEGs. Protein expression was analyzed by Western blot.
Exposure to BAI of 2 different head and neck cancer cell lines, AMC-HN4 and AMC-HN6, induced apoptosis in association with growth inhibition, cell cycle arrest, caspase-3 activation and cytochrome c release. Significantly, data from GeneFishing PCR experiments demonstrated 10 DEGs in AMC-HN6 cells treated with BAI. Some of these DEGs turned out to encode proteins with functions related to key cellular processes.
These results indicate that BAI has strong anticancer activities on head and neck cancer cells, and the DEGs induced by BAI may become involved in BAI-induced cancer cell death.
[Show abstract][Hide abstract] ABSTRACT: There have been many epidemiological and clinical researches on chronic fatigue (CF) and chronic fatigue syndrome (CFS) since the 1990s, but such studies have been quite limited in Korea. The aim of this study was to investigate the point prevalence of CF and CFS in patients who visited community-based eight primary care clinics in Korea. The study subjects were 1,648 patients aged 18 yr and over who visited one of eight primary care clinics in Korea between the 7th and 17th of May 2001. The physicians determined the status of the subjects through fatigue-related questionnaires, medical history, physical examination, and laboratory tests. The subjects were categorized into no fatigue, prolonged fatigue, CF and then CF were further classified to medically explained CF (Physical CF and Psychological CF) and medically unexplained CF (CFS and idiopathic chronic fatigue). The point prevalence of CF and CFS were 8.4% (95% CI 7.1-9.7%) and 0.6% (95% CI 0.2-1.0%). Medically explained CF was 80.5% of CF, of which 57.1% had psychological causes. The clinical characteristics of CFS were distinguished from explained CF. CF was common but CFS was rare in community-based primary care settings in Korea.
Journal of Korean Medical Science 09/2005; 20(4):529-34. · 1.25 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: A microbial secondary metabolite, arisostatins A (As-A), was originally discovered as a substance carrying the antibiotic activity against Gram-positive bacteria and shown to possess potent anti-tumor properties. The mechanism by which arisostatins A initiates apoptosis remains poorly understood. In the present report we investigated the effect of arisostatins A on activation of the apoptotic pathway in HN-4 cells. Arisostatins A was shown to be responsible for the inhibition of HN-4 cell growth by inducing apoptosis. Treatment with 4 microM arisostatins A for 24h produced morphological features of apoptosis and DNA fragmentation in HN-4 cells. Arisostatins A caused dose-dependent apoptosis and DNA fragmentation of HN-4 cells used as a model. Treatment with caspase inhibitor significantly reduced the arisostatins A-induced caspase 3 activation. In addition, arisostatins A-induced apoptosis was associated with the generation of reactive oxygen species (ROS), which was prevented by an antioxidant NAC (N-acetyl-cysteine). These data indicate that cytotoxic effect of arisostatins A on HN-4 cells is attributable to the induced apoptosis and that arisostatins A-induced apoptosis is mediated by caspase-3 activation pathway, loss of mitochondrial transmembrane potential (DeltaPsi(m)), and release of cytochrome c into cytosol.
Biochemical and Biophysical Research Communications 10/2003; 309(2):449-56. · 2.28 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: In order to assess the determinants of non-compliance with a lipid-lowering therapy, a prospective study of the hyperlipidemic Korean subjects was carried out.
A total of 1019 patients was observed by 46 family physicians for the period of 1 year from January 1999 to January 2000. To ascertain the compliance associated with a lipid lowering drug (Simvastatin), we regularly followed up the hyperlipidemic patients at intervals of 4, 12 and 24 weeks. The criterion for evaluating compliance is to measure clinic attendance. Using a structured questionnaire, patients and physicians were asked about risk factors for the compliance.
During the first 24 weeks of treatment, the lipid-lowering medication was continued by 52.3% and discontinued by 19.7%. The remaining 28% dropped out. Patient-related factors for non-compliance were young age, current smoker, lack of low fat diet and exercise, new user, no concomitant medication, and occurrence of adverse reactions. Physician-related factors for non-compliance were low patients' satisfaction with the physician, small number of hyperlipidemic patients per month and working in a relatively small hospital.
Compliance with the lipid-lowering therapy was relatively low and several factors for non-compliance were detected.
Pharmacoepidemiology and Drug Safety 12/2002; 11(7):593-600. · 3.17 Impact Factor